Background: Irritable bowel syndrome (IBS) is a complex condition with multiple factors contributing to its aetiology and pathophysiology. Aetiologically these include genetics, life-time events and environment, and physiologically, changes in motility, central processing, visceral sensitivity, immunity, epithelial permeability and gastrointestinal microflora. Such complexity means there is currently no specific reliable biomarker for IBS, and thus IBS continues to be diagnosed and classified according to symptom based criteria, the Rome Criteria. Carefully phenotyping and characterisation of a 'large' pool of IBS patients across Europe and even the world however, might help identify sub-populations with accuracy and consistency. This will not only aid future research but improve tailoring of treatment and health care of IBS patients.
Purpose: The aim of this position paper is to discuss the requirements necessary to standardize the process of selecting and phenotyping IBS patients and how to organise the collection and storage of patient information/samples in such a large multi-centre pan European/global study. We include information on general demographics, gastrointestinal symptom assessment, psychological factors, quality of life, physiological evaluation, genetic/epigenetic and microbiota analysis, biopsy/blood sampling, together with discussion on the organisational, ethical and language issues associated with implementing such a study. The proposed approach and documents selected to be used in such a study was the result of a thoughtful and thorough four-year dialogue amongst experts associated with the European COST action BM1106 GENIEUR (www.GENIEUR.eu).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/nmo.12886 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Laboratory changes during dupilumab treatment for atopic dermatitis.
Actas Dermosifiliogr
January 2025
Dermatology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Introduction: Dupilumab is an IL-4 / IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clinical significance.
The Objective: of this study is to evaluate changes in blood eosinophils and other laboratory parameters while on dupilumab.
Gastrointestinal symptoms and disorders of gut-brain interaction in pregnancy.
Indian J Gastroenterol
January 2025
Department of Gastroenterology, Criticare Asia Multispeciality Hospital and Research Centre, Mumbai, 400 049, India.
Gastrointestinal (GI) symptoms occur frequently in pregnant women, resulting in poor quality of life. These patients frequently require co-management with the obstetrician and a physician/GI specialist. The causation is complex and multifactorial.
View Article and Find Full Text PDFLong-term efficacy and safety of sacral neuromodulation for diarrhoea-predominant and mixed irritable bowel syndrome.
Tech Coloproctol
January 2025
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus, Denmark.
Background: Irritable bowel syndrome (IBS) is a very common condition worldwide. Treatment options for severe IBS are few. Sacral neuromodulation (SNM) for patients with IBS has been shown to reduce symptoms and improve quality of life in the medium term.
View Article and Find Full Text PDFSystematic Review: Integrated Models of Care for Managing Irritable Bowel Syndrome.
Neurogastroenterol Motil
January 2025
Faculty of Medicine, Centre for Health Services Research, Centre for Online Health, The University of Queensland, Woolloongabba, Queensland, Australia.
Article Synopsis
- Integrated models of care for irritable bowel syndrome (IBS) show promise in enhancing symptoms and overall quality of life for adults with the condition.
- A review of 16 studies revealed that most integrated models involved collaboration among various healthcare professionals and utilized non-pharmacological therapies, yielding significant improvements in IBS symptoms and quality of life.
- Digital health tools, such as telephone coaching and online modules, were incorporated in some models, showcasing the adaptability of care delivery methods in managing IBS.
Classification of Irritable Bowel Syndrome Using Brain Functional Connectivity Strength and Machine Learning.
Neurogastroenterol Motil
January 2025
School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Article Synopsis
- IBS is a common condition that affects brain-gut interactions, but its brain mechanisms and diagnostic criteria are not fully understood.
- Thirty-one IBS patients and thirty healthy controls underwent fMRI scans to investigate brain connectivity changes.
- Results showed specific changes in brain regions related to pain and emotion in IBS patients, with a machine-learning model achieving 91.9% accuracy in classifying patients, suggesting potential biomarkers for better diagnosis and understanding of IBS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!